Request Meetings with US Companies

Profiles of attending companies are listed below. PLEASE CHECK THIS WEBSITE REGULARLY FOR AN UPDATED LIST.

The DEADLINE to submit your meeting requests is MAY 30th.

THE PROCESS:

  1. You will receive a confirmation email for each request made
  2. UBIFRANCE will begin processing all meeting requests from MAY 30th, 2013, and will confirm mutual interest from the other party
  3. A provisional schedule will be sent to you a few days before the event and a finalized schedule on the day of the event

If you have any questions about this process, please CONTACT US.

In order to improve your chances of meeting with the companies of your choice, make your meeting requests as specific, simple and direct as possible. Include information about what your company can offer and what your company is looking for.



Default_logo

Advantagene

Advantagene is in late-stage clinical development of immunotherapeutics for prevention of recurrence after initial surgical or radiation treatment of cancer.
More ?
COMPANY :
Advantagene is a privately held biopharmaceutical company focused on oncology and immunotherapy. The Company is based in Auburndale, Massachusetts, in the Boston area. Since its founding in 1999, the company has advanced its lead clinical programs through Phase 1/2 and has entered Phase 3 in prostate cancer. To date, private investors and grants have funded the company. The management team has extensive experience in product development, biologics regulatory and manufacturing. The team was directly involved in the early development of this novel technology. Advantagene’s main product target is for preventing the recurrence and progression of cancer. As cancer escapes the current first-line treatment options, its recurrence and progression is often the largest cause of patient morbidity and mortality. Continued progress in fighting cancer will require novel therapeutic approaches that improve current care. Advantagene’s Gene Mediated Cytotoxic Immunotherapy has shown promise in this goal. It provides the tools so the patients’ own immune systems will more efficiently recognize and attack their individual tumors. It creates a vaccine effect for immunosurveillance against minimal residual disease and micrometastases. Advantagene has encouraging efficacy results in multiple solid tumor types with little to no additional toxicity. The lead product, ProstAtak, would be the first drug with newly diagnosed prostate cancer as its primary indication.
TECHNOLOGY :
Advantagene is focused on a cancer immunotherapy to prevent tumor recurrences. A key area of unmet medical need in cancer treatment is the prevention of recurrence and elimination of occult micro-metastases after initial treatment. Cancer is a leading cause of death worldwide, with approximately 577,000 deaths estimated for the US in 2012. Essentially all cancer deaths are from recurrent or metastatic disease. The standard therapies for cancer are surgery, radiation therapy and chemotherapy, often used in combination with each other. More recently, immune-based therapies, including monoclonal antibodies, cytokines and tumor antigen vaccines, have been added to the arsenal of approaches. However, progress notwithstanding, a large proportion of patients still recur and die after initial therapy. Advantagene’s technology addresses residual disease after initial treatment. The products are based on Gene Mediated Cytotoxic Immunotherapy (GMCI), which entails local delivery of AdV-tk, an adenoviral vector expressing the Herpes Simplex thymidine kinase gene (AdV-tk) followed by a cascade of immuno-stimulatory events. GMCI generates a systemic vaccine effect against residual tumor cells and occult micrometastases. Administration consists of an intra-tumoral injection of AdV-tk followed by an anti-herpetic prodrug (e.g. Valacyclovir). AdV-tk plus prodrug cause death of local cells undergoing DNA replication or repair: tumor cells, cells damaged by radiation or chemotherapy, and endothelial cells from growing tumor vessels. Most importantly, as a result of complex interactions including the mode and context of cell death, viral delivery, and superantigen-like properties of the transgene itself, a potent immuno-stimulatory effect is generated. The resulting potent anti-tumor immune surveillance fights minimal residual disease, decreasing the incidence of cancer recurrence and progression. Advantagene personnel have conducted dozens of pre-clinical studies and more than 400 patient doses given to more than 250 patients from more than 12 Phase-1/2 clinical trials a number of tumor types, including prostate, brain, pancreatic, and ovarian cancers. Collectively, the data from this work indicate that the product is very safe, have a broad therapeutic window and will provide improved patient outcomes when used in combination with currently available procedures. Advantagene is currently enrolling a fully-blinded, placebo-controlled, randomized 711 patient pivotal Phase 3 clinical study in localized prostate cancer. The study design was reviewed by the FDA under Special Protocol Assessment (SPA), and the FDA has acknowledged that upon achieving statistical significance of the agreed endpoints, the design of this single study is appropriate for marketing approval for the prevention of prostate cancer recurrence. Data-lock is anticipated ~24 months after last patient in. Advantagene has an established large-scale manufacturing process, and a released drug product and placebo inventory sufficient to support the definitive clinical study. Clinical delivery is a simple outpatient procedure with direct injection into the prostate followed by oral pro-drugs. The process integrates seamlessly with standard of care procedures, which helps make the administration process easy, and readily adopted by physicians and patients. This is important since Advantagene believes targeting healthier, early stage patients provides a greater chance of clinical success and the opportunity to positively impact a large patient population.
OBJECTIVES :
Advantagene is currently considering multiple avenues for additional resources to accelerate patient accrual and clinical development. Its primary efforts are in co-development / commercialization partnerships but equity financing will also be evaluated.
COMPANY INFORMATION :

Close
Default_logo

Agenus

Agenus is working to help the body heal itself through the power of science.
More ?
COMPANY :
Agenus is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Between Agenus and its partners, 19 programs are in clinical development.
TECHNOLOGY :
Agenus has extensive experience in vaccine adjuvants, patient specific cancer vaccines and infectious disease vaccines with nearly 20 years of R&D, manufacturing, quality, logistics and regulatory experience. The company has invested over $600MM in product and technology development, actively participated in shaping regulatory policy (FDA guidance) for cancer vaccines, established strong KOL relationships, executed worldwide large-scale Phase 3 studies and it most recently announced a substantial collaboration with the NCI who will sponsor a large-scale randomized study ($25MM+ industry dollars) with Agenus’ cancer vaccine in glioblastoma. Importantly, Agenus has a history of forming successful partnerships with both small and large biopharmaceutical companies within and outside of the US. Agenus has a therapeutic cancer vaccine platform with an advanced-stage clinical program in glioblastoma and recently reported preliminary data from a Phase 2 clinical trial in newly diagnosed glioblastoma multiforme (GBM) patients. Patients treated with Prophage G-100 vaccine plus the standard of care showed a 146% increase in progression free survival and a 60% increase in overall survival as compared to the standard of care alone. Data from the Prophage Series trials have been consistently positive in both recurrent and newly diagnosed GBM settings, and it is the hope that this vaccine may one day become part of the standard of care. Agenus also has: • Infectious disease vaccine platform with a therapeutic vaccine for HSV-2 in Phase 2 clinical development • Vaccine adjuvant platform, with QS-21 Saponin® as its lead candidate with extensive clinical testing
OBJECTIVES :
Agenus is interested in the following in-licensing opportunities: • Preclinical through Phase 1-3 Products: Development, co-development, in-licensing, and acquisition of immunotherapies targeting cancer treatment • Marketed/Registration Stage Products: In-licensing, acquiring, launching, co-marketing, and co-promotion of proprietary medicines for treatment of cancer and cancer supportive care • Strategic Partnerships: To represent ex-US companies (focused on cancer) in the US or discuss M&A opportunities that would enhance each company’s value through synergies in commercial capabilities, pipelines, and technological platforms
COMPANY INFORMATION :

Close
Default_logo

Akrivis Technologies, LLC

Ultrasensitive Diagnostics and Targeted Therapeutics
More ?
COMPANY :
Akrivis is a privately held (LLC) biotech company committed to the early detection, diagnosis and treatment of serious and life-threatening diseases based on its patented ADAPT™ technology platform. Based in Cambridge, Massachusetts, Akrivis was co-founded in 2009 by Ban-An Khaw, PhD, Professor of Pharmaceutical Sciences at Northeastern University in Boston, and Joel Berniac, PhD, MBA, experienced medicinal scientist and executive in the Pharma industry.
TECHNOLOGY :
Akrivis’ core ADAPT™ platform is a novel, patented, nanotechnology-based technology that can target the delivery of a high payload of functional molecules to any target of interest. As a result, the flexibility of the ADAPT™ platform provides significant advantages for improved diagnosis, targeted drug delivery and monitoring of treatment efficacy: • Clinical Diagnostics: by achieving large signal amplification, both for in vitro detection and in vivo imaging; • Targeted Drug Delivery: by safely delivering and targeting high drug payloads to tumor-associated surface antigens; • Companion Diagnostics and Theranostics: by combining and fully integrating the first two applications.
OBJECTIVES :
To find R&D collaborations and partnerships in the following pre-clinical and clinical areas: - ultrasensitive in vitro detection, biomarkers - high resolution in vivo imaging - targeted drug delivery - targeting agents such as antibodies, antibody fragments and mimetics, proteins, aptamers and others - chemotherapeutic molecules
COMPANY INFORMATION :

Close
Default_logo

Applied Bioinformatics

Engineering Consultants
More ?
COMPANY :
Consultants for Biotech & Medical Devices
OBJECTIVES :
Networking
COMPANY INFORMATION :

Close
Default_logo

Cancer Genetics, Inc.

Emerging leader in cancer diagnostics dedicated to paving the way for personalized medicine.
More ?
COMPANY :
Cancer Genetics, Inc. (OTCQB: CGIX) (“CGI” or “the company”) is an emerging leader in DNA-based cancer diagnostics and is dedicated to paving the way to personalized medicine by offering clinical services and products to some of the most prestigious medical institutions and biopharma in the world. The company was founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti; and has since built on a foundation of world-class scientific knowledge and IP in solid and hematologic cancers, while also establishing research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. In May 2013, CGI launched a joint venture with The Mayo Clinic, OncoSpire Genomics with the goal to commercialize new diagnostic tests by leveraging next generation sequencing. CGI’s state of the art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. CGI offers oncology-focused services and testing in anatomic pathology, flow cytometer, cytogenetics (G-banding and FISH) and molecular diagnostics including PCR, sequencing (pyro sequencing) and CGH-arrays. Tests being developed and commercialized at CGI target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. CGI has received approval from regulatory bodies (CLIA and New York State) for clinical use for its proprietary products: The Mature B cell Neoplasms Array (MatBA®) is CGI’s lead product. This CGH-array is a common platform for detecting genomic aberrations detected in leukemia’s and lymphomas and not assessed by other methodologies. Two applications are currently available: MatBA®-CLL/SLL for chronic lymphocytic leukemia and small lymphocytic lymphoma and MatBA®-DLBCL for diffuse large B cell lymphoma. In both diseases, clinical management must be carefully devised as the patients are generally older and the diseases have a heterogeneous course. Therefore, proper risk stratification at diagnosis is highly recommended. MatBA®-CLL/SLL can aid the clinicians in defining a proper prognostic for the patients while MatBA®-DLBCL is providing some insight to current treatment outcome. Both arrays are offered as part of the Company’s Complete Program™ that includes all the most relevant tests for those malignancies. The urogenital array test intended for kidney cancer (UroGenRA™-Kidney) is designed to assess genomic aberrations that are associated with the main kidney subtypes. Clinical management of kidney cancer is directly linked to cancer subtype. However, about 15% of the cases are rendered non diagnostics. UroGenRA™-Kidney provides a clear diagnosis and aids the physicians in devising the best treatment decision for the patient. The FISH-based HPV-associated Cancer Test (FHACT™) is a unique FISH test that can aid to triage patients with HPV+ lesions by identifying biomarkers of precancerous and cancerous lesions. CGI is focused on delivering products and services that drive the highest levels of patient value. To achieve this, we have developed a corporate culture that inspires innovation, respects knowledge and fosters leadership. CGI’s full-service cancer genetic practice and path to innovation with research makes for optimal patient care and healthcare cost managements.
TECHNOLOGY :
CGI’s research focuses on the development of tests applicable to the detection of genomic abnormalities in cancer. CGI aims to provide a full service solution for oncology professionals to improve the diagnosis, prognosis, theranosis and treatment of hematological, urogenital and HPV-associated cancers. To achieve this goal, CGI has developed two categories of genomic products that are being used in the clinical setting to inform and transform cancer treatment: Array-CGH and FISH Probe. CGI has designed the Mature B-cell Neoplasm Array (MatBA®), the generic name for CGI’s Array CGH product line, to measure genetic markers at 80 specific genomic sites where genetic alterations are associated with mature B-cell neoplasms. This array is intended to support the diagnosis and prognosis of non-Hodgkin lymphoma (NHL). The MatBA® pipeline includes applications for Mantle Cell Lymphomas, and follicular lymphoma. Two other applications of MatBA® are currently available: • MatBA®-CLL, was approved by both CLIA and the state of New York as an assay for routine prognostication in cases of Chronic Lymphocytic Leukemia (CLL). This was followed by the additional approval of this assay for routine prognostication in cases of Small Lymphocytic Lymphoma (SLL). • MatBA®-DLBCL, a prognostic tool in Diffuse Large B-Cell Lymphoma (DLBCL), an aggressive lymphoma. We have identified several prognostic and theranostic biomarkers which we believe are relevant to the prognosis of DLBCL and which cannot be assessed by currently available FISH tests alone. The urogenital cancer array or UroGenRA™ is a proprietary CGH-based array for the diagnosis, prognosis and theranosis of kidney, prostate and bladder cancers. It was designed to detect gains and losses that frequently occur in genetic material in these three cancer types and has the potential to differentially diagnose and/or stratify patients to assist and guide clinical management. UroGenRA™-Kidney: specifically designed to classify renal tumors into the four main subtypes (clear cell, papillary, homophobe and oncocytoma), which is critical to patient management and treatment protocols. This allows the clinician, especially in cases where there is limited biopsy material, to diagnose renal cancer and accurately classify it into the correct subtype, provide rationale for selection among surgical and non-surgical intervention or ablation, stratify patients based on prognostic information for the advancement of renal cancer into local or regional cancer which then guides decisions on surgical intervention, and guide drug trial decisions in those with metastatic disease or “unclassified” renal cancers. Two other applications of UroGenRA™ are currently being validated: UroGenRA™-Bladder and UroGenRA™-Prostate. FISH allows for the detection of targeted DNA rearrangements commonly found in cancer, and is therefore widely used for the diagnosis, prognosis and clinical management of cancer patients. The FISH based HPV-Associated Cancer Test, or FHACT™ is designed to determine copy number changes of four particular genomic regions by FISH. These regions of DNA give specific information about the progression from HPV infection to cervical cancer, in particular the stage and subtype of disease. FHACT™ is designed to enable earlier detection of abnormal cells and can identify the additional biomarkers that allow for the prediction of cancer progression.
OBJECTIVES :
Partnership with Research institutions/ companies focused on the same challenges in cancer management. Partnership with biopharma: development of companion diagnostics Partnership with Biotech: support their effort in developing and validation diagnostic testing for a commercial setting.
COMPANY INFORMATION :

Close
Default_logo

Cerulean Pharma Inc

Winning the Fight Against Cancer with Dynamically Tumor-targeted Nanopharmaceuticals
More ?
COMPANY :
Cerulean is a platform-based, product-driven company that develops dynamically tumor-targeted nanopharmaceuticals. Our platform is designed to produce products which selectively destroy tumors while sparing healthy tissue. Our products utilize the large pores in the vasculature of tumors to enter tumors and, once inside the tumor, release drug over time. Dynamically tumor-targeted nanopharmaceuticals give patients hope for longer overall survival and better quality of life. We define winning the fight against cancer as achieving long term survival with high quality of life, and turning currently incurable cancers into manageable chronic diseases. Our nanopharmaceutical platform: Creates patent-protectable new chemical entities (NCEs) by chemically conjugating active pharmaceutical ingredients inside nanoparticles Selectively delivers the therapeutic to tumors while sparing healthy tissue Gradually releases the therapeutic within the tumor over time Appears to overcome the delivery challenges that have plagued therapeutic peptides and stymied the advancement of RNAi therapy
OBJECTIVES :
Interested in networking with French Biotech companies in the oncology space
COMPANY INFORMATION :

Close
Default_logo

FORMA Therapeutics

Targeting essential cancer pathways, creating transformative small molecule therapeutics, profounding affecting cancer treatment
More ?
COMPANY :
Since its inception in 2008, FORMA Therapeutics has assembled a formidable team of drug hunters passionate about their science and driven to create transformative cancer therapies. FORMA’s novel approach to accessing high value drug targets leverages the integration of its innovative drug discovery technologies and oncology expertise. With an emphasis on areas such as tumor metabolism, epigenetics, protein-protein interactions, and protein homeostasis, FORMA deploys an ultra-efficient discovery engine to screen over 30 targets per year and enables the rational development of a novel generation of small molecule drug candidates with qualified cellular mechanisms of action. FORMA’s success is evidenced through the partnerships it has secured with leading pharmaceutical, academic, and not-for-profit institutions: Genentech, Boehringer Ingelheim, Eisai/H3 Biomedicine, Novartis, Janssen, TGEN, and Celgene, each leveraging FORMA’s capabilities, capacity, and innovations. In 2011, FORMA was selected by Fierce Biotech as one of the top 15 most promising private biotech companies and its collaboration with Genentech voted “IN VIVO Deal of the Year.” Empowered by inspiration, hope, and determination, FORMA and its partners take on cancer to deliver meaningful solutions for patients in need.
TECHNOLOGY :
FORMA deploys an ultra-efficient discovery engine to screen over 30 targets per year (using close to 40 million wells/year) and enables rapid parallel drug discovery across target families. FORMA’s discovery team exploits several core capabilities: Structural biology and proprietary in silico CS Mapping to identify features of interest and guide medicinal chemistry; simultaneous HTS using both biochemical and proprietary cell-based (MAPPIT) formats for protein-protein interactions; a highly unique small molecule Compound Archive consisting of (i) a diversity compound set, (ii) DOS compounds having stereo-chemical richness akin to natural products with ease of synthesis of combinatorial chemistry, and (iii) shape-directed, protein domain- and target family-based libraries generated using CS Mapping data; a state-of-the-art high speed solution phase parallel synthesis & purification platform, with annual capacity over 100,000 molecules (at 5-10 mg) to support library and medicinal chemistry efforts, and having physical properties and in vitro ADME profiling capacity of ~1000 compounds per week. FORMA’s portfolio focuses on tumor metabolism, epigenetics, protein homeostasis and selected protein-protein interactions. Working within defined and overlapping pathways allows us to effectively leverage knowledge and diminish risk across target families. Our engine uses an iterative process including computational and medicinal chemistry, parallel synthesis, X-ray crystallography and translational biology studies to deliver high quality, drug-like molecules suitable for advancing into development. FORMA’s pipeline efforts over 15 months have resulted in seven projects entering into full lead optimization (primarily based on large pharma-defined lead optimization criteria), the initiation of a series of new target screens and several targets exiting the portfolio using our rigorous attrition model.
OBJECTIVES :
Business Development
COMPANY INFORMATION :

Close
Default_logo

GCA Therapeutics, Ltd

GCA Therapeutics Ltd (GCAT) is a US based, specialty pharmaceutical company focusing on in-licensing, acquisition and marketing of mid through late stage drug candidates and technologies from North America and the EU.
More ?
COMPANY :
GCA Therapeutics Ltd (GCAT) is a US based, specialty pharmaceutical company focusing on in-licensing, acquisition and marketing of mid through late stage drug candidates and technologies from North America and the EU. GCAT applies its expertise and resources in pre-clinical, clinical, and final regulatory review and approval phases to commercialize products for use in the Chinese market. GCAT is currently in discussion with several US and European biotech and pharma firms to bring several important drugs to market through its joint venture in Tianjin, China. Initially, GCAT will market its products through a 3rd party distribution/sales partnership and will construct or acquire manufacture capabilities in China at a later date. GCAT currently has operations in New Jersey, New York, Shanghai, and Beijing.
OBJECTIVES :
Licencing and investment opportunities
COMPANY INFORMATION :

Close
Default_logo

GLG Pharma, LLC

Combining diagnostics with drugs for cancer and other proliferative diseases
More ?
COMPANY :
GLG Pharma is interested in BTB relationships in France. It has the opportunity to license an EU approved drug for the treatment of skin cancer as well as developing drugs for inhibition of STAT3 within France. It has formed an SAS and would like to have it funded to launch sales of the approved product and further develop its pipeline products in cancer in France for sales throughout the EU, using France as a manufacturing site as well as a development site. GLG can do this through its own funding of the project (ongoing now) or with a potential French company partner.
TECHNOLOGY :
Skin Cancer - Approved EU product - license for France, Latin America, Canada and Japan available. Starting in France. OTC- Rosacea and psoriasis. Currently sold in Germany, Arabia, Sweden, Denmark etc. License for France. GLG-801 a re-purpose drug for CLL coupled with GLG diagnostic. Also use in ADPKD a rare disease that has 100% STAT3 upregulation which our compounds inhibit. GLG-302 - Potential development with French cancer center for proof of concept- Solid tumors. Needs BTB partner or French investment GLG-202 - Next product in line for STAT3 inhibition Diagnostic - immunohistochemistry to develop in CLIA labs for monitoring patients then develop into ELISA kit. Would like to couple with our efforts in France to develop GLG-302 and GLG-202.
OBJECTIVES :
Meet potential French BTB partners and investors for our immediate revenue opportunities in France and development of GLG pipeline products and diagnostics in France.
COMPANY INFORMATION :

Close
Default_logo

IndUS Pharmaceuticals

Discovery and development of novel small molecule anticancer drugs derived from natural product research
More ?
COMPANY :
A cross-border start-up enterprise that couples technologies from US and Indian institutes of research towards the discovery and development of novel anticancer drugs. These novel drugs are 'synthetic lethal' in resistant cancer cells that have loss of tumor suppressor function.
TECHNOLOGY :
A platform company leveraging natural product research based on antitumor antibiotics coupled with novel biological breakthroughs, leading to novel first-in-class anticancer drugs.
OBJECTIVES :
Partnerships with companies seeking exclusive rights for commercialization of novel drugs from our portfolio in various territories to allow global development and commercialization of our novel drug candidates.
COMPANY INFORMATION :

Close
Default_logo

Ipsen

Innovation driven Specialty Pharma company with focus on hormone related targeted debilitating disease indications.
More ?
COMPANY :
Paris, France based mid-size Specialty pharma company with annual revenues of ~1.2B Euros and about 4500 employees with world wide locations. Our footprint includes presence in over 114 countries with direct presence in 66 countries two key R/D centers in Les Ulis, France and Milford, MA, USA.
OBJECTIVES :
Network with both French and US based companies for developing potential partnerships of mutual interest.
COMPANY INFORMATION :

Close
Default_logo

Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center is a quasi-public agency of the Commonwealth of Massachusetts.
More ?
COMPANY :
The Center was established to promote the life sciences within the Commonwealth of Massachusetts. It is tasked with investing in life sciences research and economic development. This work includes making financial investments in public and private institutions growing life sciences research, development and commercialization as well as building ties between sectors of the Massachusetts life sciences community.
OBJECTIVES :
We are looking to help identify companies from the Alsace region in France who may be interested in an International Collaborative R&D project with an MA company.
COMPANY INFORMATION :

Close
Default_logo

MSM Protein Technologies

MSM Protein Technologies is an antibody drug discovery, early development company.
More ?
COMPANY :
MSM Protein Technologies is 8 years old privately held an antibody drug discovery, early development company.
TECHNOLOGY :
Our proprietary fully-integrated technology platform allows for rapid and reliable generation of human therapeutic antibodies using phage display libraries. Recently, the platform was extended to mammalian cell display libraries and immunization approaches. Our pipeline is mainly focused on immunologic and oncologic diseases including: • Blood cancers and solid tumors such as acute T-cell lymphoblastic leukemia (T-ALL), diffuse large B-cell lymphoma (DLBCL), melanoma, glioma, pancreatic cancer and gastric cancer. • Graft-versus-host disease (GVHD). • Autoimmune diseases associated with Th17 cells like multiple sclerosis (MS), psoriasis, rheumatoid arthritis. • Respiratory diseases such as idiopathic pulmonary fibrosis (IPF), human respiratory syncytial virus (RSV), chronic obstructive pulmonary disease (COPD) and asthma.
OBJECTIVES :
The company is seeking partners for de novo discovery as well as to advance our proprietary antibodies for the treatment of oncologic, autoimmune, inflammatory and respiratory diseases into clinical development.
COMPANY INFORMATION :
  • Address :
      MSM Protein Technologies, Inc. 10A Roessler Road - 01801 Woburn - MA
  • Website :
     http://msmprotein.com/

Close
Default_logo

NKT Therapeutics Inc

Precisely targeting the interface between innate and adaptive immunity.
More ?
COMPANY :
NKT Therapeutics, Inc. is a biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (“NKT”) cells. NKT cells are a rare but central component of the immune system that plays a pivotal role in human health and disease. Upon exposure to glycolipid antigens, NKT cells secrete high levels of specific cytokines that stimulate the innate and adaptive arms of the immune system to eliminate these pathogens. During periods of repeated exposure to immune challenge, NKT cells play a regulatory role controlling the type and magnitude of the adaptive arm of the immune system to regulate antibody and cell mediated immunity. Recent evidence has clearly established the importance of NKT cells in human health and disease. The mission of NKT Therapeutics is to use the Company’s expertise to develop a pipeline of first-in-class NKT based therapeutics to treat sickle cell anemia, autoimmune diseases and inflammatory diseases, cancer, asthma and dermatitis.
TECHNOLOGY :
We are targeting a unique subset of T cells called NKT cells which offers the opportunity to develop selective immune modulators with the potential to treat cancer, infectious disease, autoimmune diseases (e.g, SLE, T1D, MS, IBD), asthma and dermatitis. Our lead program is a based upon a unique antibody that targets the invariant T cell receptor. Depending on the effector function of the antibody, we can either activate or deplete NKT cells. We are developing antibody therapeutics that can both activate and inactivate NKT cell function. We are currently in a Phase 1b study in sickle cell disease with our iNKT cell depleting antibody NKTT120.
OBJECTIVES :
Learn more about French biotechnology
COMPANY INFORMATION :

Close
Default_logo

Paloma Pharmaceuticals, Inc.

Small molecule drug company focused on first-in-class allosteric inhibition of the TORC1 and TORC2 complexes of the PI3K pathway.
More ?
COMPANY :
Clinical stage biotechnology company developing drugs targeted primarily in ophthalmology, oncology and dermatology.
OBJECTIVES :
Business development
COMPANY INFORMATION :

Close
Default_logo

RAN Biotechnologies, Inc.

Design and synthesis of solid media for selective capture, detection and controlled release of microorganisms and proteins
More ?
COMPANY :
RAN Biotechnologies provides speciality chemicals for biotechnological applications. Of particular interest to us are solid media capable of immobilizing biologicals. The related research was initiated by the founder, Dr. Roger Nassar, while in the Chemistry Department at the Massachusetts Institute of Technology. Dr. Nassar’s previous work focused on preparing and characterizing pure materials, in addition to developing knowledge around the related mechanistic processes and conditions for bond formation and de-stabilization. Such a wide background is instrumental for the success of RAN Biotechnologies projects.
TECHNOLOGY :
The broad impact of our materials will reach therapeutic, prophylactic, diagnostic and microbe purification applications. Current therapies and prophylactic preventions of infectious diseases involve the use of hazardous chemicals and energy-consuming technologies. In addition to eliminating target microbes, the applied chemicals spread systemically in the human body and the environment leading to undesired harmful side effects. The class of microbe-capturing materials to be validated herein has the potential to disinfect fluids without generating such side effects. This type of materials could be used in Pathogen Inactivation in fusion blood, or could be packed in an extra-corporeal cartridge for in-vivo blood disinfection. Also, using proper eluents, active microbe particles can be controllably released from the proposed materials. Such characteristic is of great interest to the vaccine purification industry. The broad impact of our materials will reach therapeutic, prophylactic, diagnostic and microbe purification applications. Current therapies and prophylactic preventions of infectious diseases involve the use of hazardous chemicals and energy-consuming technologies. In addition to eliminating target microbes, the applied chemicals spread systemically in the human body and the environment leading to undesired harmful side effects. The class of microbe-capturing materials to be validated herein has the potential to disinfect fluids without generating such side effects. This type of materials could be used in Pathogen Inactivation in fusion blood, or could be packed in an extra-corporeal cartridge for in-vivo blood disinfection. Also, using proper eluents, active microbe particles can be controllably released from the proposed materials. Such characteristic is of great interest to the vaccine purification industry.
OBJECTIVES :
We are open for all possibilities.
COMPANY INFORMATION :

Close
Default_logo

Shire

To be as brave as the people we help
More ?
COMPANY :
There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives. This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine. This might be a therapy to treat an extremely rare and life-threatening disease like Hunter syndrome or Fabry disease; or a medicine for a specialist condition like ADHD or ulcerative colitis; or a treatment to help the healing of diabetic foot ulcers which if not treated effectively, can dramatically affect the lives of the patient and their whole family. Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients.
OBJECTIVES :
Networking
COMPANY INFORMATION :
  • Address :
      300 Shire way - 02420 Lexington - MA
  • Website :
     http://shire.com

Close
Default_logo

Synta Pharmaceuticals Corp.

Synta's mission is to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases
More ?
COMPANY :
Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a pipeline of small molecule drug candidates with novel chemical structures and distinct mechanisms of action. All drug candidates were invented internally by Synta scientists using our compound library and discovery capabilities. Our lead compound, ganetespib is a second-generation, small molecule inhibitor of heat shock protein 90 (Hsp90), a chaperone regulating numerous proteins that drive tumor growth and proliferation. Over 700 patients have been treated to date across 20 trials for ganetespib. Single-agent clinical activity has been observed in multiple tumor types including ALK+ NSCLC, HER2+ and triple negative breast cancer. Randomized studies are ongoing in 2nd line adenocarcinoma NSCLC in combination with docetaxel.
OBJECTIVES :
Partnering opportunities.
COMPANY INFORMATION :

Close
Default_logo

UBIFRANCE

French Agency for International Business Development
More ?
COMPANY :
As a member of the French diplomatic network in the United States, UBIFRANCE is at the heart of the apparatus designed to help French companies export on the US market.
OBJECTIVES :
Empower interactio between French and American entities
COMPANY INFORMATION :

Close